Zydus Lifesciences Limited has informed the Exchange regarding a press release dated February 19, 2026, titled "Zydus launches biosimilar Aflibercept 2 mg ANYRA for advancing ophthalmic care ".
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Zydus Lifesciences has announced the launch of its biosimilar Aflibercept 2 mg under the brand name ANYRA in India. Aflibercept is used to treat serious eye conditions such as wet age-related macular degeneration and diabetic macular edema. The product is a biosimilar version of the innovator biologic Eylea, which is a high-value drug globally. This launch expands Zydus's specialty ophthalmology portfolio and supports its strategy to grow its biosimilars business in India.
Likely positive for the stock as it adds a new, high-margin product in a growing ophthalmology segment; however, meaningful revenue contribution will depend on market share capture and pricing in a competitive segment.